ProQR Therapeutics (PRQR) Capital Expenditures Growth (1y) (2014 - 2026)
ProQR Therapeutics (PRQR) Capital Expenditures Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 143.40% |
| 10 | ProQR Therapeutics | 185.96 Mn | 93.68 Mn | - | -26.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.79% |
| Dec 31, 2025 | -43.99% |
| Sep 30, 2025 | 40.91% |
| Jun 30, 2025 | -62.17% |
| Mar 31, 2025 | 130.60% |
| Dec 31, 2024 | 26.31% |
| Sep 30, 2024 | 15.63% |
| Jun 30, 2024 | 190.82% |
| Mar 31, 2024 | -438.24% |
| Dec 31, 2023 | 49.76% |
| Sep 30, 2023 | -37.80% |
| Jun 30, 2023 | -27.27% |
| Mar 31, 2023 | -155.74% |
| Dec 31, 2022 | 735.11% |
| Sep 30, 2022 | -40.57% |
| Jun 30, 2022 | -344.23% |
| Mar 31, 2022 | 862.50% |
| Dec 31, 2021 | -90.68% |
| Sep 30, 2021 | 33.71% |
| Jun 30, 2021 | 84.88% |